Lawsuit probes Alnylam over slowing drug sales and stock drop after Q3 report

Pomerantz LLP is investigating Alnylam Pharmaceuticals for potential securities fraud following the company's Q3 2026 report, which showed slowing demand for its key drug Amvuttra. This drug accounts for 87.5% of Alnylam's sales, and the reported U.S. demand growth fell from $129 million to $81 million quarter-over-quarter. The news caused Alnylam's stock to drop 25.13% on October 29, 2026. The investigation may impact investor confidence and future company disclosures.

Alnylam Pharmaceuticals shares continue to face pressure following recent negative news, trading down 2.66% on Pluang. The stock is priced at USD 152.45 with a market cap of $20.98 billion as of Nov 11, 2026 06:11 WIB.